Eculizumab for a catastrophic relapse in NMOSD: case report
Authors:
- 27 July 2023
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (1) , 249-251
Abstract
Neuromyelitis optica spectrum disorders (NMOSD) are a group of inflammatory disorders of central nervous system characterized by immune-mediated demyelination and axonal damage, predominantly affecting spinal cord and optic nerves. This case report describes a 47-year-old woman with an aggressive form of seropositive NMOSD who had previously been treated with corticosteroids, plasma exchange, and cyclophosphamide. She experienced a life-threatening relapse that did not respond to conventional treatment, but ultimately showed a positive response to eculizumab. Furthermore, we describe the role of sNfL.Keywords
This publication has 9 references indexed in Scilit:
- Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosisJournal of Neurology, 2023
- Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysisMultiple Sclerosis and Related Disorders, 2022
- Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case reportFrontiers in Neurology, 2022
- Trial of Satralizumab in Neuromyelitis Optica Spectrum DisorderNew England Journal of Medicine, 2019
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialThe Lancet, 2019
- Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum DisorderNew England Journal of Medicine, 2019
- Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disordersMultiple Sclerosis and Related Disorders, 2018
- Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)Journal of Neurology, 2013
- Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis OpticaJAMA Neurology, 2013